Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia
| Autor: | Orietta Spinelli, Piera Viero, Renato Bassan, Marie Lorena Guinea Montalvo, Elena Maino, Manuela Tosi, Barbara Peruta, Margherita Parolini, Anna Maria Scattolin, Alessandro Rambaldi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Chemotherapy medicine.medical_specialty Cure rate MRD Response business.industry medicine.medical_treatment Hematology Minimal residual disease Transplantation hemic and lymphatic diseases Internal medicine Immunology Adult Acute Lymphoblastic Leukemia medicine Pharmacology (medical) Stem cell business Clinical risk factor |
| Zdroj: | International Journal of Hematologic Oncology. 3:419-431 |
| ISSN: | 2045-1407 2045-1393 |
| Popis: | SUMMARY While adult acute lymphoblastic leukemia (ALL) is curable in 40–50% of the patients, the individual prognosis is rather unpredictable due to associated biological and clinical risk factors. In both B- and T-precursor ALL, minimal residual disease (MRD) represents the most sensitive prognostic marker, useful to support critical treatment decisions, ranging from allogeneic stem cell transplantation in patients with inadequate MRD response to chemotherapy only in MRD responsive ones. This optimized risk-adapted strategy allows to spare transplant-associated morbidity and mortality in patients curable by chemotherapy. Further progress is expected from the integration of the MRD-based strategy with improved pediatric-type regimens and novel targeting agents for discrete ALL subsets. These changes are increasing the cure rate to above 50%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|